A short list of the abstracts that will actually change something in clinic this year, rather than everything that got a plenary slot.
Myeloma
Bispecific antibodies moved further up the treatment sequence, and the infection-prophylaxis data finally caught up with the efficacy data.
Lymphoma
Longer follow-up on CAR-T in second line continues to look durable in the group that responded early.
Benign haematology
Gene therapy for sickle cell disease dominated the conversation, with access and cost as the live questions rather than efficacy.
